

Design	K-EVEREST	CONSTANT
Study type	21 Centers, prospective, nonrandomized observational registry including PCI with CoCr-EES	7 Centers, prospective, nonrandomized observational registry including PCI with Re-ZES
Stent name	Xience V™	Resolute-Integrity™
Stent type used for PCI	Cobalt-chromium everolimus-eluting stents	Zotarolimus-eluting stents
Main inclusion criteria	DS for epicardial coronary artery $\geq 70\%$, or 50%–70% with objective evidence of myocardial ischemia; diameter stenosis for left main coronary artery $\geq 50\%$, and amenable to PCI.	
Exclusion criteria	The exclusion criteria were minimal. Patients with cardiogenic shock, malignant disease, or other comorbid conditions with a life expectancy of <12 months; those treated with a mixture of different types of DES; and those with planned surgery necessitating interruption of antiplatelet drugs within 6 months after the procedure were excluded.	
Recruitment period	Feb 2009–Apr 2011	Jul 2011–Dec 2013
Follow-up period (median and IQR), y	2.03 (1.96–2.08)	2.02 (1.97–2.07)

Abbreviations: DES, drug-eluting stents; DS, diameter stenosis; CoCr-EES, cobalt-chromium everolimus-eluting stent(s); IQR, interquartile range; Re-ZES, Resolute zotarolimus-eluting stent(s).